Evidence map›Paper›PMID 36316777›Full record

ArticleVirology journal2022

Human adenoviral (HAdV) chronic arthritis expands the infectious spectrum of primary agammaglobulinemia.

Grégoire Martin de Frémont, Maud Salmona, François Maillet, Margaux Garzaro, Rémi Bertinchamp, Arthur Simonnet, Linda Feghoul, Guitta Maki, Marie Roelens, Emilie Chotard and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Grégoire Martin de FrémontClinical Immunology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Maud SalmonaVirology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
François MailletClinical Immunology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Margaux GarzaroClinical Immunology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Rémi BertinchampClinical Immunology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Arthur SimonnetClinical Immunology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Linda FeghoulVirology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Guitta MakiImmunology Laboratory, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Marie RoelensCentre d'étude des déficits immunitaires (CEDI), Hôpital Necker, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Emilie ChotardRheumatology Department, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris (AP- HP), Université Paris Cité, Paris, France.
Capucine PicardCentre d'étude des déficits immunitaires (CEDI), Hôpital Necker, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Eric OksenhendlerClinical Immunology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
Jérôme LeGoffVirology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
David BoutboulClinical Immunology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France. david.boutboul@aphp.fr.
Université Paris Cité · FRHôpital Saint-Louis · FRAssistance Publique – Hôpitaux de Paris · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inborn errors of immunity (IEI) are a heterogeneous entity with an increasing number of late diagnoses. Besides infections, inflammatory manifestations are a growing part of the clinical landscape of IEI. These complications are of unknown causes and often lead to the prescription of immunosuppressive agents that worsen the underlying immune defect. We here report the case of an adult patient diagnosed with chronic Human Adenovirus C-1 arthritis in the setting of primary agammaglobulinemia. Metagenomic next-generation sequencing led to the correct diagnosis and high-dose intravenous immunoglobulins resulted in complete recovery. This observation gives new insights into adenoviral immunity and underlines the importance of metagenomics in the diagnosis of inflammatory manifestations in immunocompromised patients.

Indexed as

Adenoviruses, HumanAgammaglobulinemiaArthritisAdenoviridaeAdultHumansImmunoglobulins, IntravenousImmunoglobulins, IntravenousAdenoviral arthritisAgammaglobulinemiaInborn errors of immunityMetagenomic next generation sequencing

Identifiers

PMID36316777
PMCPMC9623974
OpenAlexW4307744995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.